A randomized controlled trial on the benefits and respiratory adverse effects of morphine for refractory dyspnea in patients with COPD: Protocol of the MORDYC study

Research output: Contribution to journalArticleAcademicpeer-review

1 Citation (Scopus)

Abstract

Dyspnea is one of the most reported symptoms of patients with advanced Chronic Obstructive Pulmonary Disease (COPD) and is often undertreated. Morphine has proven to be an effective treatment for dyspnea and is recommended in clinical practice guidelines, but questions concerning benefits and respiratory adverse effects remain. This study primarily evaluates the impact of oral sustained release morphine (morphine SR) on health related quality of life and respiratory adverse effects in patients with COPD. Secondary objectives include the impact on exercise capacity, the relationship between description and severity of dyspnea and the presence of a clinically relevant response to morphine, and cost-effectiveness.

A single-center, randomized, double blind, placebo controlled intervention study will be performed in 124 patients with COPD who recently completed a comprehensive pulmonary rehabilitation program. Participants will receive 20-30 mg/24 h morphine SR or placebo for four weeks. After the intervention, participants will be followed for twelve weeks. Outcomes include: the COPD Assessment Test, six minute walking test, Multidimensional Dyspnea Scale and a cost diary. Furthermore, lung function and arterial blood gasses will be measured. These measures will be assessed during a baseline and outcome assessment, two home visits, two phone calls, and three follow-up assessments. The intervention and control group will be compared using uni- and multivarlate regression analysis and logistic regression analysis. Finally, an economic evaluation will be performed from a societal and healthcare perspective. The current manuscript describes the rationale and methods of this study and provides an outline of the possible strengths, weaknesses and clinical consequences. (C) 2016 Elsevier Inc. All rights reserved.

Original languageEnglish
Pages (from-to)228-234
Number of pages7
JournalContemporary Clinical Trials
Volume47
DOIs
Publication statusPublished - Mar 2016

Keywords

  • Chronic Obstructive Pulmonary Disease
  • Dyspnea
  • Morphine
  • Research protocol
  • Clinical effectiveness
  • Adverse effects
  • OBSTRUCTIVE PULMONARY-DISEASE
  • SUSTAINED-RELEASE MORPHINE
  • QUALITY-OF-LIFE
  • EXERCISE TOLERANCE
  • QUESTIONNAIRE PFSDQ
  • FUNCTIONAL STATUS
  • PALLIATIVE CARE
  • LUNG-DISEASE
  • BREATHLESSNESS
  • OPIOIDS

Cite this